Bluemtec, a pharmaceutical e-commerce company, said it will start co-marketing two MSD’s vaccines  -- one for hepatitis A the other for Measles, Mumps, and Rubella (MMR) –- in Korea from January 1, 2024.

Bluemtec will co-market MSD’s vaccines through its subsidiary BluePharm Korea from the start of next year.
Bluemtec will co-market MSD’s vaccines through its subsidiary BluePharm Korea from the start of next year.

This marks the first joint vaccine sale between a local distributor and a global pharmaceutical company.

The vaccines will be supplied through BluePharm Korea, a pharmaceutical e-commerce platform for hospitals and clinics operated by Bluemtec.

As of the third quarter of 2023, BluePharm Korea had a registration rate of 58.7 percent among nationwide clinics. Ninety-five percent of these registered clinics fall under the pediatric, internal medicine, and family medicine departments, all of which demonstrate a notably high vaccination rate.

"We will collaborate to contribute to the prevention of infectious diseases in Koreans through the stable supply of vaccines essential for the National Immunization Program (NIP),” MSD Korea Managing Director Albert Kim said.

Bluemtec CEO Jung Byung-chan also said, “I am pleased that with the introduction of the two vaccines, BluePharm Korea will be able to supply these as one of the main products for the NIP.”

The company will strive to ensure a smooth supply of essential vaccines through close collaboration with MSD Korea, Jung added.

Copyright © KBR Unauthorized reproduction, redistribution prohibited